XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue Recognition (Tables)
3 Months Ended
Jun. 30, 2021
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

Three Months Ended June 30, 2021

 
  

Sterilization and Disinfection Control

  

Biopharmaceutical Development

  

Instruments

  

Continuous Monitoring

  

Total

 

Discrete Revenues

                    

Consumables

 $12,876  $3,608  $942  $10  $17,436 

Hardware and Software

  160   3,557   5,238   1,844   10,799 

Services

  701   582   1,382   853   3,518 

Contracted Revenues

                    

Services

  1,413   1,130      624   3,167 

Total Revenues

 $15,150  $8,877  $7,562  $3,331  $34,920 
  

Three Months Ended June 30, 2020

 
  

Sterilization and Disinfection Control

  

Biopharmaceutical Development

  

Instruments

  

Continuous Monitoring

  

Total

 

Discrete Revenues

                    

Consumables

 $11,484  $1,939  $808  $30  $14,261 

Hardware and Software

  129   2,556   5,020   1,955   9,660 

Services

  250   782   1,852   531   3,415 

Contracted Revenues

                    

Services

  1,204   672   -   729   2,605 

Total Revenues

 $13,067  $5,949  $7,680  $3,245  $29,941 
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
  

Three Months Ended June 30,

 
  

2021

  

2020

 

United States

 $18,455  $16,372 

Foreign

  16,465   13,569 

Total revenues

 $34,920  $29,941 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

Contract liabilities as of March 31, 2021

 $8,994 

Prior year liabilities recognized in revenues during the quarter ended June 30, 2021

  (2,448)

Contract liabilities added during the quarter ended June 30, 2021, net of revenues recognized

  3,144 

Contract liabilities balance as of June 30, 2021

 $9,690